Methods and Protocols

    Analysis of 12 polycyclic aromatic hydrocarbons in THS aerosol

    PMI

    Published on
    Mar 14, 2017
    Topic
    Summary

    The aerosol samples are generated with a linear smoking machine and collected on a Cambridge filter pad. Polycyclic aromatic hydrocarbons (PAHs) are then extracted with hexane after addition of internal standards. The aerosol extract undergoes a two steps solid-phase extraction (SPE) clean-up procedure in order to remove some matrix co-extracted organic compounds that reduce the performance of the chromatographic system and affect the accuracy of PAHs determination. The resulting extracts are analyzed by Gas Chromatography with Electron Impact Mass Spectrometry (GCEI-MS). The GC system is equipped with a column DB-17MS column, 30 m x 0.25 mm ID x 0.15 μm (film thickness). Results are expressed as ng/item for the Tobacco Heating System (THS), referred to as Platform 1 (P1) in the method.

    Related Publications

    Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System 2.2

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

    Aerosol Chemistry

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.